Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT06866691

Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide

Led by Wake Forest University Health Sciences · Updated on 2026-04-24

600

Participants Needed

1

Research Sites

101 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to assess the incidence of early post-traumatic seizures. The study will also assess the benefit of lacosamide compared to levetiracetam in regards to agitation and behavioral adverse effects in patients with traumatic brain injury requiring seizure prophylaxis.

CONDITIONS

Official Title

Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years and older
  • Diagnosed with traumatic brain injury, including severe, moderate, or mild with high-risk imaging features
  • Will receive seizure prevention treatment with either levetiracetam or lacosamide within 24 hours of injury
  • Admitted to the trauma team service
Not Eligible

You will not qualify if you...

  • Currently enrolled in another interventional drug study
  • Had any active or witnessed seizure or seizure cannot be ruled out before starting seizure prevention
  • Received antiseizure medication before randomization
  • History of seizures
  • Taking anti-epileptic medications for seizures or other reasons before admission
  • History of alcohol withdrawal or currently experiencing alcohol withdrawal requiring treatment
  • Have spinal cord injury confirmed by imaging (cervical C1-C8 or thoracic T1-T12)
  • History of slow heart rate (bradycardia), permanent pacemaker, or heart rate under 55 bpm for more than 5 minutes not caused by medication
  • End-stage kidney disease
  • Death, withdrawal of life support, or transfer to hospice within 24 hours
  • Pregnant or incarcerated
  • Baseline Glasgow Coma Scale (GCS) below 13 or unable to determine GCS
  • Patient or authorized representative unable to provide informed consent before randomization or unable to read and understand English, Spanish, Vietnamese, Russian, Arabic, or French

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States, 27157

Actively Recruiting

Loading map...

Research Team

B

Bailey Baswell, BS

CONTACT

R

Rita Brintzenhoff, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here